Rick Simpson Oil (RSO) in Dededo: The Complete Guide by OilWell Cannabis

If you’re reading this in Dededo, chances are you’ve heard about Rick Simpson Oil from a neighbor, a family member at a fiesta, or maybe during a conversation at the Hagåtña market. Maybe you’re a veteran stationed at Andersen Air Force Base dealing with chronic pain that the clinic can’t fully address. Maybe you’re a Chamorro elder looking for alternatives to the handful of pills you’ve been prescribed. Or maybe you’re a young parent on Guam watching someone you love battle cancer, and you’re desperate for honest answers about what RSO can and cannot do.

We get it. We’ve been there. Not in Dededo specifically — our roots are in Houston, Texas — but we’ve lived the same story of watching conventional medicine fall short and finding hope in cannabis when nothing else worked. This guide is our way of reaching across the Pacific to Dededo with the same transparency and education we give our customers in Montrose, because people everywhere deserve the truth about RSO, not hype.

About Rick Simpson and Traditional Rick Simpson Oil

Who is Rick Simpson

Rick Simpson was born in 1949 in Nova Scotia, Canada. He wasn’t a doctor or scientist — he was a blue-collar power engineer, the kind of hardworking man you might find repairing generators at GUMA or maintaining hospital equipment at Guam Memorial. In 1997, while working at a hospital in Moncton, Simpson fell from scaffolding and suffered a serious head injury. The aftermath included persistent tinnitus and dizziness that doctors couldn’t fix. The medications made it worse, and when he asked his physician about cannabis, the doctor refused to even discuss it. Sound familiar? It’s the same story we hear from Dededo patients who’ve been dismissed by providers who don’t understand cannabis.

Simpson’s interest in concentrated cannabis oil deepened after learning about a 1974 NIH-funded study at the Medical College of Virginia, where THC was reported to slow or shrink tumors in mice. That study — originally intended to demonstrate harm — became his North Star, even though its findings were never replicated in controlled human cancer trials. For Dededo residents researching cannabis online, you’ll encounter this 1974 study cited frequently. It’s real, but it’s also where the evidence stops.

The pivotal moment came in 2003 when Simpson claimed that three bumps on his arm, diagnosed as basal cell carcinoma, disappeared after applying cannabis oil for four days. No biopsy confirmation, no peer-reviewed documentation, no independent medical verification. Yet this personal testimony became the origin story of RSO and remains the emotional anchor that draws people in Dededo and everywhere else to search for “RSO cancer cure.”

Important context: Simpson’s account is presented here as his personal testimony. While historically significant, the absence of clinical documentation means these events cannot be evaluated as medical evidence. We say this plainly because Dededo deserves honesty, not fairy tales.

The crusade — spreading the oil

After his 2003 experience, Simpson committed himself to producing and distributing concentrated cannabis oil from his property in Maccan, Nova Scotia. He gave it away for free — to cancer patients, chronic pain sufferers, people with diabetes, infections, glaucoma, arthritis, depression, insomnia. He charged nothing. This free-distribution model is crucial for Dededo residents to understand because it explains why RSO became a global movement. In a place like Guam, where the cost of living is high and many families live paycheck to paycheck, the idea of free medicine resonates powerfully.

Simpson’s story reached a global audience through the 2005 documentary Run From The Cure, which was distributed freely online. For many in Dededo, that film — shared on Facebook or shown at community gatherings — was their first introduction to RSO. It framed cannabis oil as grassroots medicine challenging pharmaceutical interests.

But this advocacy brought legal conflict. The Royal Canadian Mounted Police raided Simpson’s property in 2005 and 2009. He was charged with cultivation, possession, and trafficking, facing the same kind of felony penalties that Guam residents could encounter under federal law if caught with Schedule I substances. Eventually, he left Canada for Europe, living in Croatia and the Netherlands, continuing his advocacy from exile. This history matters in Dededo because it shows the legal risk that defined early cannabis advocacy — a risk that still shadows anyone considering importing cannabis products to Guam.

Simpson published his story in 2012’s Phoenix Tears and maintained phoenixtears.ca as his information hub. Throughout his career, he maintained an uncompromising position: RSO could cure cancer, and pharmaceutical companies, government agencies, and medical institutions were actively suppressing this knowledge.

Important context: Simpson’s conspiratorial framing is noted here without endorsement or dismissal. It reflects a worldview shared by many in the early cannabis movement and is relevant to understanding RSO’s cultural significance. In Dededo, where trust in institutions has been tested by everything from military contamination issues to healthcare access challenges, this skepticism resonates. Our job isn’t to dismiss it but to provide the evidence so you can decide.

The traditional RSO protocol — Simpson’s 60-gram, 90-day regimen

Simpson’s core recommendation was to consume 60 grams of concentrated cannabis oil over roughly 90 days. He described this as a cancer treatment protocol, though he recommended it for other conditions too.

Goal: Consume 60 grams over approximately 90 days.

Titration schedule:

• Week 1: Half a grain of rice-sized dose (10-15 mg) three times daily = 30-45 mg total
• Weeks 2-5: Double every four days until reaching 1 gram per day (1,000 mg)
• Weeks 5-12: Maintain 1 gram daily, divided into three 333 mg doses

Administration methods:

• Primary: Oral/sublingual swallowing
• Secondary: Topical for skin cancers
• Not recommended: Smoking/vaping as primary treatment

Tolerance and psychoactive effects: Simpson claimed patients develop tolerance in 3-4 weeks and recommended nighttime dosing initially to sleep through the high. He warned against driving during titration.

Post-protocol maintenance: 1-2 grams per month indefinitely.

Dietary recommendations: Reduce sugar, avoid processed foods — general wellness advice, not a specific protocol.

Important context for evaluating this protocol

This protocol has major limitations Dededo residents must understand:

• No controlled trial validation. Zero published randomized controlled trials, cohort studies, or well-documented case series.
• Crude, unstandardized material. Every batch varied based on plant genetics, growing conditions, and extraction technique.
• Very high THC exposure. At peak dosing (600-900 mg delta-9 THC daily), this far exceeds anything studied clinically. The FDA-approved synthetic THC drug dronabinol is typically dosed at 2.5-20 mg per day.
• Real risks at these doses. Severe intoxication, anxiety, panic, tachycardia, hypotension, and cannabis use disorder are well-documented at high THC doses [1][13][14][15].

For Dededo residents considering this protocol: please work with your healthcare provider at Guam Memorial Hospital or your private clinic. Using unregulated, unstandardized cannabis oil as primary cancer treatment — potentially in place of proven therapies — introduces harm that extends beyond the oil itself.

What is traditional Rick Simpson Oil — the product

Traditional RSO was defined by Simpson’s method, not lab specifications:

Source material: High-THC indica strains, no standardization. Whatever he grew or sourced.

Extraction solvent: Naphtha (petroleum-based lighter fluid) or 99% isopropyl alcohol. Neither is food-grade. Naphtha may contain benzene, toluene, and other carcinogens. This is one of the most significant safety concerns with traditional RSO — especially relevant in Dededo where the humid climate can affect storage and solvent evaporation.

Extraction process: Bucket, solvent wash, filter through cheesecloth, evaporate in a rice cooker at 60-80°C. The heat decarboxylated THCa to THC and destroyed most terpenes.

Appearance: Nearly black, thick, tar-like, sticky oil with strong cannabis odor and possible solvent-residual smell.

Cannabinoid profile: 60-90% delta-9 THC (estimated), with minor cannabinoids at natural ratios — uncontrolled, unmeasured, never lab-verified.

Terpene content: Minimal to none. The solvent + heat process stripped them away.

Standardization and testing: None. Every batch was different. No COA, no potency testing, no contaminant screening.

Residual solvent risk: Incomplete solvent purging leaves potentially harmful residues. Without lab testing, impossible to verify. Modern extraction uses food-grade ethanol or CO₂ to address this.

Simpson’s claims vs. the evidence record

Simpson claimed RSO could cure cancer and many other diseases. Let’s evaluate this against actual evidence.

What Simpson was not: He had no medical training, no clinical trials, no peer-reviewed publications. His evidence was personal experience and testimonials — no controls, no independent verification, no long-term follow-up.

What the preclinical literature shows: In vitro and animal studies show THC and CBD can induce apoptosis, inhibit proliferation, and reduce angiogenesis in certain cancer cell lines . Animal models show some tumor-growth inhibition. This is scientifically interesting but not proof of human cancer cures.

What the preclinical literature does NOT show: These findings have not translated into proven human cancer cures. The gap between in vitro/animal results and human outcomes is vast. No human clinical trial has demonstrated RSO or any cannabis oil cures cancer .

Institutional positions:

• U.S. National Cancer Institute (NCI): Acknowledges cannabinoid anticancer research in labs but does not endorse cannabis as cancer treatment .
• FDA: Has not approved any cannabis plant product for cancer. Only Epidiolex (CBD for seizures) and synthetic THC analogues for chemo nausea and AIDS wasting [1].
• Health Canada: Never approved RSO for cancer.
• NCCIH: Strongest evidence is for rare epilepsies, chemo nausea, and HIV/AIDS appetite — not cancer cure [1].

What Simpson got right: He drew attention to cannabinoids as serious biomedical research when the world ignored it. He helped create conditions for legal cannabis and made RSO a household term. That legacy matters in Dededo because whatever cannabis access exists here today — however limited — exists partly because of the movement he helped spark.

What he overstated: The leap from preclinical signals to cancer cure was never supported by human evidence. Encouraging patients to use RSO instead of proven oncologic therapies (surgery, radiation, chemo, immunotherapy) carries genuine harm potential. Delayed or foregone treatment for treatable cancers is a documented concern in alternative medicine literature.

The legacy of Rick Simpson and the evolution of modern RSO

The term “RSO” is now used loosely across the legal cannabis industry. Many products labeled RSO bear little resemblance to what Simpson made. In dispensaries, RSO can refer to almost any full-spectrum extract in a syringe.

Simpson was critical of commercial products departing from his method. He believed in DIY, free-access medicine — grow your own, extract your own, treat yourself without corporate intermediaries. This philosophical tension is real. Whether modern commercialization represents improvement (quality control, testing) or betrayal (profit, gatekeeping) depends on perspective. The cannabis community remains divided.

What is not disputed: modern RSO has evolved substantially, and those changes matter for Dededo residents seeking safe, effective products.

Traditional RSO vs. modern formulated RSO

Dimension	Traditional RSO	OilWell formulated RSO
Source material	Single high-THC indica strain	Multi-cannabinoid blend from multiple sources
Extraction method	Naphtha or isopropyl alcohol	Modern food-grade ethanol or CO₂ methods
Cannabinoid profile	THC-dominant, uncontrolled	Seven defined cannabinoids at specific ratios
Terpene content	Destroyed by high-heat process	Live terpenes at 5% with defined seven-terpene profile
Standardization	None — every batch different	Lab-tested with specific mg/mL targets (553 mg/mL)
Lab testing	Not available or performed	Full panel testing for potency, terpenes, pesticides, heavy metals, residual solvents, microbial contaminants
Residual solvents	Significant risk with naphtha	Controlled and tested, solvent-free production
Dosing precision	Approximate, syringe-based	Measured per mL with known cannabinoid content
Product formats	Single thick oil only	Sublingual oil and vape cartridge with format-specific formulas
THCa preservation	No — fully decarboxylated by heat	Yes — THCa included as separate ingredient at 1,500 mg
Evidence approach	Anecdotal, personal testimony	Research-backed, evidence-weighted

Why OilWell’s formulas diverge from traditional RSO

Our formulations are not traditional RSO. They depart deliberately based on evidence:

Multi-cannabinoid approach: Simpson used single strain; we include seven cannabinoids (CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, CBC) because entourage-effect literature suggests benefit from cannabinoid diversity, even if robust clinical proof remains limited [20][29].

Terpene preservation: Traditional RSO had no terpenes; we include live terpenes at 5% with a specific seven-terpene profile because terpene bioactivity is plausible and supported preclinically [20][21][23][24][25][26][27][28][29].

THCa as separate ingredient: Traditional RSO fully decarboxylated everything; we preserve THCa at 1,500 mg because its evidence profile suggests anti-inflammatory and neuroprotective potential distinct from THC [12].

Reduced delta-9 THC dominance: Traditional RSO was 60-90% delta-9 THC; our sublingual formula uses only 90 mg delta-9 THC total, distributing the remaining content across other cannabinoids to reflect broader research rather than single-compound dominance.

Product format innovation: Simpson had oral oil only; we offer sublingual oil and vape cartridge, acknowledging that different delivery routes have different pharmacokinetic profiles [14].

Solvent safety and extraction evolution

Traditional RSO used naphtha or isopropyl alcohol — neither food-grade. Naphtha contains benzene, toluene, and other toxic compounds. Incomplete solvent purging leaves harmful residues. In Dededo’s humid climate, improper storage of solvent-contaminated products could increase health risks.

Modern extraction uses food-grade ethanol or CO₂ with validated analytical testing. OilWell’s RSO is not an extraction product — it’s a formulated blend of individual cannabinoid distillates and isolates combined in controlled conditions. No solvents in the finished product. We use organic MCT oil as carrier, eliminating the tar-like consistency and solvent-residual odor of traditional RSO.

Third-party lab testing covers potency, terpenes, pesticides, heavy metals, residual solvents, and microbial contaminants. COAs are available on request and through our website.

The decarboxylation question

Traditional RSO was fully decarboxylated by heat, converting all THCa to THC. Our sublingual formula preserves THCa at 1,500 mg as a distinct ingredient, creating three usage options:

Option 1 — Raw, no heat: All 1,500 mg stays as THCa — non-psychoactive. Provides anti-inflammatory activity via COX-2 inhibition and neuroprotective potential via PPARγ agonism [12]. Compatible with work, driving, daytime use in Dededo with zero impairment.

Option 2 — Fully activated, home decarboxylation: Heat oil at 260°F (125°C) for 45-60 minutes in an oven-safe glass container. Converts 1,500 mg THCa to ~1,315 mg delta-9 THC. Combined with existing 90 mg delta-9 THC = ~1,405 mg total delta-9 THC. Combined with 6,000 mg delta-8 THC, this delivers psychoactive potency comparable to traditional illegal RSO — 100% legally, because decarboxylation occurs at your discretion after purchase. You can decarb only what you intend to use, preserving the remainder raw.

Option 3 — Vape, auto-decarboxylation: Our vape cartridge vaporizes at 400-450°F, instantly converting THCa to delta-9 THC with each puff. Every inhalation delivers freshly decarboxylated cannabinoids — fastest-onset RSO delivery available.

Conversion chemistry: 1 mg THCa = 0.877 mg delta-9 THC after decarboxylation (accounting for CO₂ loss).

This design puts potency control in your hands — aligning with Simpson’s principle that patients should control their medicine, but implementing it through actual chemistry rather than one-size-fits-all.

About OilWell Cannabis and the OilWell RSO Formula

The origin of OilWell Cannabis

OilWell Cannabis was founded by Colin Valencia in Houston, Texas. Our story begins in McAllen, Texas — right across the river from Reynosa, Tamaulipas, Mexico. The McAllen-Reynosa Borderplex is one of the most economically challenged and dangerous regions along the U.S.-Mexico border. McAllen is a city of contrasts — vibrant culture and thriving retail, yet deeply affected by poverty and limited opportunities outside retail and healthcare. Reynosa is an industrial hub plagued by violence and cartel activity.

Colin’s childhood in McAllen was marked by exposure to both opportunities and challenges. Early on, he learned to hustle, taking on risky work in transporting items across the border. Those experiences exposed him to complexities and dangers. Many of his best friends have been killed or are in prison because of associated dangers. He has faced every form of violence imaginable, both in the streets and across the border. By sixteen, he had to leave home for good.

Despite the dangers, Colin didn’t fall into darker paths like selling harder substances. He focused on cannabis, seeing it as safer and more beneficial. He grew up in the traditional cannabis world long before legalization, learning the plant intimately while operating in the shadows. Over time, he transitioned from those early, risky ventures to creating a legal, legitimate business in an industry he believes in.

Colin later became a formally trained software engineer and did custom development work for Baylor College of Medicine, one of the most prestigious medical institutions in the Texas Medical Center. That combination — deep cannabis plant knowledge plus medical-grade technical precision — defines OilWell’s approach.

Bentley’s story: The real origin of OilWell

Our company origin story begins with a dog named Bentley. Bentley was more than a pet — he was family, a companion who stood by Colin through the toughest times. When Bentley fell seriously ill, veterinarians delivered the verdict no pet owner wants to hear: euthanasia was the only humane option. Bentley was paralyzed in his back legs. They said the pain medications would destroy his internal organs, causing more pain and suffering. The choice was painful prolonged decline or immediate mercy killing.

But giving up on Bentley was not an option. In a desperate search for alternatives, Colin stumbled upon CBD through a question that changed everything. A rescue worker named Jessica asked: “You’ve moved how many tons of weed and you’ve never heard of CBD?”

Colin had cannabis experience — but it was recreational. He’d never explored therapeutic applications. Jessica’s question exposed a blind spot that became a mission.

Determined to save Bentley, Colin learned to create CBD golden paste — a specialized cannabinoid formula for pets. It was not a cure, but it was a lifeline. And that hope delivered something veterinary medicine said was impossible: Bentley got up. He walked over to Colin and brought him his ball to play. From paralyzed and facing euthanasia to fetching his ball. This was not placebo effect — dogs do not respond to placebo. This was cannabinoid medicine doing what pharmaceuticals could not.

Bentley lived another ten years, passing naturally at age twenty. During those years, Colin developed specialized cannabis formulas for every age-related condition Bentley faced. Neurodegeneration led him to understand CBG’s neuroprotective properties and THCa’s PPARγ agonism for brain cell protection. Dementia led him to CBC’s role in neurogenesis. Glaucoma led him to THC’s CB1 agonism for intraocular pressure reduction. Crippling arthritis led him to develop multi-pathway anti-inflammatory approaches using CBD, CBG, THCa, and beta-caryophyllene working through different receptor systems simultaneously.

Single cannabinoids were not enough. Bentley’s evolving conditions required multi-cannabinoid synergy. CBD alone could not address neurodegeneration and dementia and glaucoma and arthritis simultaneously. Minor cannabinoids like CBG, CBN, and CBC became critical as Bentley aged. Pharmaceutical precision mattered — Bentley’s life depended on formula accuracy, not guesswork.

Bentley’s journey was Colin’s entry into cannabis beyond getting high. It became a mission to create real solutions that help alleviate pain and suffering, not just for pets but for people. Bentley’s story is the foundation of OilWell Cannabis, driving our commitment to quality, innovation, and compassionate care.

Colin’s personal journey: PTSD and benzo addiction

Colin also knows pharmaceutical dependence personally. He struggled with PTSD and benzodiazepine addiction. When he decided to break free from Xanax, he did it cold turkey — notoriously difficult and dangerous — using the cannabinoid knowledge he developed keeping Bentley alive.

The Peace Gummies formula that became an OilWell product was created during midnight experiments while fighting through benzo withdrawal. Colin personally uses the vape form for insomnia and severe PTSD on an ongoing basis. This is not theoretical knowledge. Colin lived what RSO patients live: desperation for relief, failed pharmaceuticals, the discovery that cannabinoids work when pills do not.

Over time, the therapeutic benefits of cannabis that Colin first discovered through his efforts to save Bentley became the core of his work. He has developed formulas that doctors use for conditions like Crohn’s disease, IBS, ulcerative colitis, PTSD, benzo addiction, and insomnia. His focus has always been on making cannabis accessible and effective for everyone, including vegans, diabetics, and those with specific health needs.

ABC13 media recognition

Between September 2019 and April 2023, ABC13 Houston — the ABC affiliate serving America’s fourth-largest city — featured Colin and OilWell Cannabis in seven distinct news segments. Five different reporters sought us out across those years. No other Houston cannabis operator appears with that frequency or breadth.

September 15, 2019 — “Texas CBD businesses booming”: Our first feature. Colin’s quote became our philosophy: “I’m not trying to sell people snake oil. I’m not trying to sell people hope. But there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

March 22, 2021 — “Entrepreneur creates direct-to-consumer business”: Colin as ecosystem builder, helping other entrepreneurs like Jonathan Pina. The quote: “Pain comes in a lot of different forms” — speaks to every Dededo community dealing with any form of suffering.

May 24, 2021 — “What is Delta 8 THC”: Steve Campion’s investigative piece. When asked why someone would want to smoke Delta-8, Colin’s iconic reply: “I don’t give a sh* if it’s wrong to say you’ll get high off it. Maybe you want to get high.”* Radical honesty on mainstream TV.

August 20, 2021 — “COVID vaccine giveaway”: We gave away 1,000 special edition caviar pre-rolls (approximately $35,000 in product) to encourage vaccination in Houston, coordinated with city government, no political strings attached.

October 19, 2021 — “Delta-8 ban”: Overnight, Delta-8 became Schedule I in Texas. Colin proactively removed all products and warned other operators who were unknowingly shipping Schedule I narcotics. Absorbed major revenue loss to act ethically.

October 7, 2022 — “Biden marijuana pardon”: Colin revealed his personal marijuana conviction history. The article opened with our CBD vending machine innovation, then delivered the most personal dimension: “You face challenges with housing, loans, and banking, I mean with about everything.” Every quote about therapy and education carries more weight knowing this lived experience.

April 21, 2023 — “Marijuana industry getting creative”: Colin growing hemp on camera, explaining the “Renaissance” happening right now. Featured in 4/20 coverage as Houston’s cannabis authority.

This media record demonstrates consistency across years, breadth of expertise, community action, personal stakes, and evolution. These features cannot be purchased — they are earned recognition from a major-market ABC affiliate that repeatedly identified Colin as the most credible voice in Houston’s legal cannabis industry.

Current operations

Today, OilWell Cannabis operates from Montrose, Houston, Texas (810 Richmond Avenue, Houston, TX 77006). We’ve been operating since 2019, generate approximately $1 million in annual revenue, maintain a near-5.0 Google rating, and are Texas DSHS licensed. All artwork, formulations, and packaging are created in-house in Houston. We bring Houston grit, McAllen roots, and a builder’s mindset to everything we do, but our posture stays simple: make products with intent, answer directly, and never pretend cannabis is right for everyone.

The OilWell RSO philosophy

Our RSO is not traditional Rick Simpson Oil. It is a formulated, multi-cannabinoid product informed by the RSO tradition but departing from it in deliberate, evidence-motivated ways.

1. Accessibility over gatekeeping. No medical card required. Anyone age 21+ can purchase. We ship nationwide and internationally to customers who verify local legality — including to Dededo, Guam. Simpson believed medicine should be accessible to everyone; we built a product and distribution model that makes that accessible legally.

2. Patient-controlled potency. THCa is sold in its acidic, non-psychoactive form. You decide whether to use it raw for non-psychoactive benefits or decarboxylate it into delta-9 THC for full psychoactive potency. This is especially valuable in Dededo where many residents work in federal jobs, tourism, or the military and need functional daytime relief without impairment.

3. Open-source formulas. We publish complete formulas publicly — every cannabinoid, every milligram, every percentage — so anyone who cannot afford the product can source ingredients and make their own. Simpson gave his oil away free and taught people to make it; we adapted that ethos for the modern marketplace by selling a professionally manufactured product and publishing the recipe.

4. Evidence-informed, not evidence-overstating. The GENERAL KNOWLEDGE section in this document represents our commitment to honest education about what science actually says. Simpson operated without peer-reviewed literature access; we have that access and use it to distinguish what is well-supported, what is emerging, and what is overstated.

Farm Bill compliance and the THCa legal framework

The 2018 Farm Bill legalized hemp and hemp-derived products containing less than 0.3% delta-9 THC by dry weight at the federal level. This is the foundation of our product design.

Our RSO Sublingual Oil contains only 90 mg delta-9 THC in the entire 30 mL bottle — 3 mg per mL — well under the 0.3% threshold. All cannabinoids are hemp-derived. The product is legal under federal law and in most states, including shipment to U.S. territories like Guam.

For Dededo residents specifically: Guam’s cannabis laws permit the use of medical marijuana with a Guam Medical Marijuana Card, but access remains limited. Our Farm Bill-compliant products provide a legal pathway for Guam residents age 21+ to access high-potency cannabinoid formulations without needing a medical card or dealing with the island’s limited dispensary infrastructure.

THCa is the acidic, non-psychoactive precursor to delta-9 THC. It is not itself delta-9 THC, making it Farm Bill compliant at point of sale. This distinction is legally significant.

The practical significance: You can decarboxylate THCa into delta-9 THC at home by heating the oil at 260°F (125°C) for 45-60 minutes in an oven-safe glass container. This converts 1,500 mg THCa into approximately 1,315 mg delta-9 THC. Combined with the existing 90 mg delta-9 THC, this produces approximately 1,405 mg total delta-9 THC — giving the product psychoactive potency comparable to traditional illegal RSO, entirely at your discretion after legal purchase.

This means the same product can function as non-psychoactive anti-inflammatory (used raw) or full-potency psychoactive cannabinoid product (after home decarboxylation). You control the decision. The product is legal everywhere all component cannabinoids are legal, which enables international shipping to jurisdictions like Guam with compatible hemp laws.

Important legal notice for Dededo customers: THCa converts to delta-9 THC when heated. You are responsible for understanding and complying with Guam law regarding cannabinoid products. OilWell ships with full documentation, Certificates of Analysis, and receipts. Guam customers accept all customs and legal responsibility.

Open-source formulas — why we publish everything

We publish our complete RSO formulas publicly — every cannabinoid, every milligram amount, every percentage — so that anyone who cannot afford the product can source ingredients and make their own version.

This is a direct echo of Rick Simpson’s original ethos. He gave his oil away free and taught people to make it. He never patented his method. We adapted that ethos for the modern marketplace: sell a professionally manufactured, lab-tested, standardized product for those who want it, and publish the complete recipe for those who want to make it themselves.

As Colin said on ABC13 in 2019: “I’m not trying to sell people snake oil. I’m not trying to sell people hope. But there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

The open-source philosophy started with Bentley. On our About Us page, we published the actual CBD golden paste recipe that saved Bentley’s life, so any pet owner facing a similar crisis could make it:

CBD golden paste recipe for pets — the original open-source formula

Ingredients:

• 1/2 cup organic turmeric powder
• 1 cup water
• 1/3 cup coconut oil (unrefined, organic)
• 1 to 2 teaspoons freshly ground black pepper (important for absorption)
• CBD oil (dosage depends on pet size and needs; consult a veterinarian)

Instructions:

1. Mix turmeric and water in a saucepan over low heat, stirring continuously until thick paste forms (7-10 minutes). Add water if too thick.
2. Add coconut oil and pepper, stir until thoroughly mixed.
3. Cool and store in a jar with lid in refrigerator for up to two weeks.
4. Add CBD oil to paste before giving to pet, adjusting dosage by weight. Start low and gradually increase. Mix with pet’s food once or twice daily. Monitor and consult a veterinarian if concerns arise.

This recipe — published free, years before the RSO formulas — demonstrates that open-source is foundational, not a marketing strategy.

The decarboxylation choice — patient-controlled potency

Traditional RSO was always fully decarboxylated. Our sublingual formula creates three distinct usage options:

Option 1 — Raw, no heat: All 1,500 mg stays as THCa — completely non-psychoactive. Provides anti-inflammatory and neuroprotective benefits [12]. Compatible with daytime work, driving, parenting in Dededo with zero impairment. Essential for federal employees, military personnel, and anyone needing functional relief.

Option 2 — Fully activated, home decarboxylation: Heat at 260°F for 45-60 minutes in oven-safe glass. Converts 1,500 mg THCa to ~1,315 mg delta-9 THC. Combined with existing 90 mg = ~1,405 mg total delta-9 THC. Combined with 6,000 mg delta-8 THC, delivers potency comparable to traditional illegal RSO — 100% legally, because decarboxylation occurs after purchase. You can decarb only what you intend to use.

Option 3 — Vape, auto-decarboxylation: Our vape cartridge vaporizes at 400-450°F, instantly converting THCa to delta-9 THC with each inhalation. Every puff delivers freshly decarboxylated cannabinoids — fastest-onset RSO delivery available. Ideal for breakthrough pain, panic attacks, or acute nausea that Dededo residents may experience.

Conversion chemistry: 1 mg THCa = 0.877 mg delta-9 THC after decarboxylation.

This design empowers you — whether you’re a teacher at Okkodo High School, a construction worker in Tamuning, or a retiree in Yigo — to choose the experience that fits your life.

Solvent-free production

Our RSO is not an extraction product. It’s a formulated blend of individual cannabinoid distillates and isolates combined in controlled conditions. No naphtha. No isopropyl alcohol. No butane. No extraction solvents in the finished product.

This eliminates the residual solvent risk that is one of the most significant safety concerns with traditional RSO — especially relevant in Dededo’s humid climate where contaminants could proliferate.

We use organic MCT oil (medium-chain triglycerides) as carrier. MCT oil is food-grade, facilitates sublingual absorption, and provides neutral taste — a significant improvement over traditional RSO’s tar-like consistency and solvent-residual odor.

Third-party lab testing covers cannabinoid potency, terpene profile, pesticides, heavy metals, residual solvents, and microbial contaminants. Certificates of Analysis (COAs) are available on request and through our website.

The broader OilWell product portfolio

Beyond RSO, we produce:

Asshole Peach — Our most popular product. Delta-8, Delta-9, Delta-10, THCo, CBD, and CBG in peach gummy rings. Particularly favored by veterans for PTSD and pain relief. If you’re a veteran in Dededo who served at Andersen or Naval Base, this formula was developed with your needs in mind.

Peace Gummies — Developed directly from Colin’s benzo withdrawal experience. Contains CBN, Delta-9, Delta-8, CBD, and CBG. Available in gummy and vape form. Colin personally uses the vape to manage his insomnia and severe PTSD.

Custom creations — We design tailored products on request for specific cannabinoid ratios, delivery formats, or health circumstances. This includes formulations for vegans, diabetics, and those with specific dietary needs common in Dededo’s diverse community.

Two product formats

RSO Sublingual Oil — $129.99

• 30 mL bottle (1 fl oz)
• 16,590 mg total cannabinoids (553 mg/mL)
• Seven cannabinoids: CBD 4,500 mg, CBG 3,000 mg, delta-8 THC 6,000 mg, THCa 1,500 mg, delta-9 THC 90 mg, CBN 750 mg, CBC 750 mg
• Live terpenes at 5%: limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene
• Organic MCT oil base
• Graduated dropper for precise 0.1 mL dosing
• Onset: 15-45 minutes (sublingual)
• Peak: 1-2 hours
• Duration: 4-6 hours
• Bioavailability: 13-19%
• 40-60 doses per bottle depending on serving size

RSO Vape Cartridge — $49.99

• 1-gram cartridge
• 900+ mg total cannabinoids
• Six-cannabinoid ratio (same as sublingual but auto-decarbs THCa)
• Live terpenes at 5%+
• 510-thread universal battery compatibility
• Onset: 1-2 minutes (fastest delivery)
• Peak: 10-15 minutes
• Duration: 2-4 hours
• Bioavailability: 10-35%

When to use each format in Dededo

Use case	Recommended format	Rationale
Fast relief (acute pain, nausea, panic)	Vape	1-2 minute onset — crucial when you need immediate relief before a family gathering at the beach
Sustained relief (chronic pain, sleep)	Sublingual	4-6 hour duration — keeps you comfortable through a full day at work or evening with family
Maximum bioavailability	Sublingual	13-19% absorption for efficient use of every milligram
Portability/discretion	Vape	Compact, no measuring — fits in your pocket for discreet use anywhere on island
Precise dosing control	Sublingual	Graduated dropper in 0.1 mL increments — perfect for titrating your exact therapeutic window
Daytime non-psychoactive use	Sublingual (raw)	THCa stays inactive, zero impairment — essential for federal employees, military, or anyone driving in Dededo traffic
Nighttime psychoactive use	Sublingual (decarbed) or Vape	Activated THCa + delta-8 THC for full therapeutic strength while you sleep

Competitive comparison — why OilWell is different for Dededo

OilWell RSO vs. Texas medical cannabis (TCUP):

• TCUP requires medical card with qualifying conditions (cancer, PTSD, epilepsy, etc.)
• OilWell: Age 21+ only, no medical card required — accessible to Dededo residents who don’t qualify for Guam’s limited medical program
• TCUP: THC-only products
• OilWell: 7 cannabinoids including CBG, CBN, CBC, delta-8 THC, and THCa
• TCUP: Must travel to physical dispensary
• OilWell: Ships directly to Dededo, Guam with full documentation

OilWell RSO vs. hemp CBD RSO (e.g., Lazarus Naturals):

• Their 10 mL bottle: 1,000 mg total cannabinoids
• Our 30 mL bottle: 16,590 mg total cannabinoids (16x more potent)
• Their product: Minimal psychoactive option
• Our product: Patient-controlled activation delivers 1,405 mg delta-9 THC potential
• For Dededo residents seeking serious therapeutic impact, concentration matters when shipping costs are higher

OilWell RSO vs. traditional illegal RSO:

• See the eleven-dimension comparison table in the Rick Simpson section. Every row shows why modern formulation is safer, more precise, and more effective.

Condition-specific usage context for Dededo residents

Important disclaimer: These usage contexts are informed by cannabinoid research cited in our GENERAL KNOWLEDGE section. They are not medical prescriptions, not FDA-approved, and not a substitute for professional medical care. Always consult your healthcare provider at Guam Memorial Hospital, a private clinic in Tamuning, or your primary care physician before using cannabinoid products. Do not operate vehicles or machinery while under the influence of psychoactive cannabinoids.

Chemotherapy-related nausea and appetite support (for cancer patients at GMH or seeking treatment off-island):

• Pre-chemo: 0.5-1.0 mL sublingual approximately 1 hour before treatment
• Acute breakthrough nausea: 2-3 vape puffs for immediate relief (1-2 minute onset)
• Post-chemo: 0.5 mL sublingual every 6 hours as needed
• Sleep support during treatment: 1.0-2.0 mL sublingual before bed (delivers 25-50 mg CBN)

Chronic pain (common in Dededo’s construction, tourism, and military workforce):

• Daytime: 0.3-0.5 mL raw sublingual — anti-inflammatory without psychoactive impairment, perfect for working at the port or in hospitality
• Nighttime: 0.5-1.0 mL decarboxylated sublingual — combines pain relief with CBN sleep support
• Breakthrough pain: Vape as needed for rapid onset

Sleep support (for Guam’s many shift workers and those with family stress):

• Before bed: 1.0-2.0 mL sublingual
• At 2.0 mL, this delivers 50 mg CBN — the dosage investigated in 2024 sleep literature
• At 1.0 mL, this delivers 25 mg CBN — above the threshold associated with reduced sleep disturbance

Anxiety and stress (PTSD is prevalent in Guam’s veteran community):

• Daytime functional relief: 0.3 mL raw sublingual — CBD and CBG address anxiety pathways without impairment
• Nighttime: 1.0 mL sublingual — full cannabinoid profile including CBN for sleep architecture
• Evidence from veteran users in Houston suggests this combination helps manage hypervigilance and intrusive thoughts

General titration principle for Dededo: Start low, go slow. Begin with 0.25-0.5 mL sublingual and assess effects over 2-3 hours before increasing. Individual responses vary based on body weight, metabolism, tolerance, concurrent medications, and genetic factors common in Pacific Islander populations.

Delivery and global accessibility to Dededo, Guam

We are proud to offer international shipping to Guam, including Dededo. While we cannot provide same-day delivery across the Pacific like we do in Houston, we can get our products to you reliably and legally.

Shipping to Dededo, Guam:

• USPS Priority Mail International: 6-10 business days
• FedEx International Economy: 4-6 business days
• UPS Worldwide Expedited: 3-5 business days
• All packages include full documentation, Certificates of Analysis, and receipts for Guam Customs
• Temperature-stable packaging for tropical climates
• Tracking provided for all orders
• Signature-required option available

For Guam residents: The THCa legal framework makes this possible. Because our product contains less than 0.3% delta-9 THC at point of sale, it meets the definition of a hemp-derived product under the 2018 Farm Bill and is shippable to U.S. territories with compatible hemp laws. You are responsible for verifying Guam’s specific regulations and accepting all customs and legal risk.

Important for Dededo: Guam’s remote location means shipping costs are higher than mainland U.S. This is why our 16,590 mg total cannabinoid concentration matters — you’re getting maximum therapeutic value per dollar spent on shipping. A single bottle provides 40-60 doses, making it cost-effective despite freight costs.

Customs and documentation: We provide complete COAs showing cannabinoid content, confirming delta-9 THC remains under 0.3% threshold. This documentation is crucial for Guam Customs clearance. We’ve successfully shipped to multiple Pacific islands and understand the documentation requirements.

How the OilWell formulas connect to the evidence

Every cannabinoid in our formula — CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, CBC — has its own evidence profile in our GENERAL KNOWLEDGE section. Every terpene — limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene — is covered with preclinical and review-level evidence.

The formulas are anchored to per-compound evidence summaries. We do not exempt ourselves from the same evidence standards applied to the broader field. Our position — as stated in 2019 — is that people deserve the best possible version of information so they can give it a fair shot and decide for themselves whether it’s right or wrong for them.

This document is the research foundation for that position. It is more than a product guide; it is a commitment to integrity, creativity, and the mission that started when Bentley got up, walked across the room, and brought his ball to play.

General Knowledge: Cannabinoid and Terpene Evidence

Research method and evidence weighting

We prioritize sources in this order: human clinical evidence, systematic reviews and meta-analyses, NIH and institutional summaries, then mechanistic or preclinical literature. This weighting matters because the evidence base is uneven. CBD and delta-9 THC have the strongest human literature; delta-8 THC, THCa, CBG, CBN, CBC, and most terpenes depend more on reviews, animal work, and in vitro pharmacology [1]-[29].

Institutional baseline from NIH

• NCCIH states strongest cannabinoid evidence is for rare epilepsies, chemo nausea/vomiting, and HIV/AIDS appetite/weight loss. Modest evidence exists for chronic pain and MS symptoms. Many claimed uses remain early-stage research [1].
• FDA has not approved the cannabis plant itself for medical use, though purified CBD (Epidiolex) and synthetic THC analogues have specific approvals [1].
• Safety concerns highlighted by NIH include impairment, motor vehicle crash risk, cannabis use disorder, pregnancy concerns, accidental pediatric exposure, contamination, labeling inaccuracy, and THC-vape lung injury [1].
• NCCIH warns over-the-counter CBD products may differ from labels and CBD itself has been associated with decreased alertness, GI effects, liver injury, and drug interactions [1].

Cannabinoid profiles

CBD:

• Best supported: Purified CBD has strongest human evidence in seizure disorders [1][2].
• Anxiety: 2024 systematic review of 316 participants across eight studies reported significant anxiolytic signal but stressed limited clinical sample [3].
• Pain: 2024 systematic review concluded promising but heterogeneous literature, limiting broad analgesic claims [4].
• Sleep: 2023 insomnia review found methodologically weak literature with few objective assessments [5].
• Safety: 2023 systematic review found signal for liver enzyme elevation and possible drug-induced liver injury, especially relevant for concentrated oral products and polypharmacy settings [6].
• Bottom line: Most evidence-developed nonintoxicating cannabinoid, but strong evidence is concentrated in specific indications, not broad wellness claims [1]-[6].

CBG:

• Evidence: Mostly review-level and preclinical; human evidence sparse [7][8].
• Pharmacology: CBG is biosynthetic precursor to several cannabinoids, interacts with cannabinoid receptors, alpha-2 adrenoceptors, and 5-HT1A signaling — mechanistically interesting but not clinically established [7].
• Research areas: Reviews discuss possible relevance to neurologic disorders, inflammatory bowel disease, and antibacterial activity — primarily pharmacology-led hypotheses [7][8].
• Caution: CBG is sold commercially while evidence base remains thin; claims frequently outrun science [7].
• Bottom line: Serious research topic, but should be described as promising minor cannabinoid with limited clinical validation [7][8].

Delta-8 THC:

• Evidence: Pharmacologically relevant, psychoactive, much less clinically characterized than delta-9 THC [9]-[11].
• Comparative pharmacology: 2022 review concluded delta-8 and delta-9 have broadly similar pharmacokinetic and pharmacodynamic behavior. Delta-8 is partial CB1 agonist, less potent than delta-9 likely due to weaker CB1 affinity [9].
• Public health: 2023 scoping review found evidence base dominated by animal studies, product chemistry, use reports, and public-health concerns rather than strong human trials. Noted reports of adverse consequences and emphasized regulatory/product-quality concerns [10].
• Manufacturing: 2024 chemistry review reinforces commercial delta-8 interest tied to greater stability and easier synthesis relative to naturally scarce plant levels, raising product-byproduct and lab-testing questions [11].
• Bottom line: Psychoactive THC analogue with real pharmacologic activity, incomplete human safety characterization, more manufacturing-quality uncertainty than consumers realize [9]-[11].

THCa:

• Evidence: Important chemically/formulation-wise, but low on direct human therapeutic evidence [12].
• What it is: Acidic precursor of THC, may represent large share of THC-related content in raw plant material. Decarboxylates to THC during heating and can change during storage/processing [12].
• Psychoactivity: THCa itself does not produce psychoactive effects associated with THC in humans, but distinction only holds if molecule stays acidic and is not substantially decarboxylated [12].
• Research status: In vitro and rodent literature suggest anti-inflammatory, immunomodulatory, neuroprotective, and antineoplastic possibilities, but not equivalent to established human outcomes [12].
• Bottom line: Highly relevant precursor molecule whose interpretation depends heavily on route, temperature, processing, and storage. Any claim must account for possible conversion to THC [12].

Delta-9 THC:

• Evidence: Strongest human evidence of psychoactive cannabinoids, but also clearest adverse-effect burden [1][13]-[15].
• Institutionally supported: NCCIH identifies relevance to chemo nausea/vomiting, HIV/AIDS appetite/weight loss, some MS and pain outcomes, while stressing many other uses remain uncertain [1].
• Pain evidence: 2022 systematic review found high-THC or comparable THC:CBD products may provide short-term pain benefit but increased dizziness, sedation, nausea, and treatment discontinuation [13].
• Pharmacokinetics: Inhaled THC: effects within seconds-minutes, peak 15-30 minutes, taper over few hours. Oral THC: later onset, later peak, longer duration — matters for both benefit and overconsumption risk [14].
• Mental health risk: 2025 systematic review of high-concentration THC products found consistent unfavorable associations with psychosis/schizophrenia outcomes and cannabis use disorder, with concerning signals for anxiety and depression [15].
• Broader safety: Anxiety/panic at high doses, tachycardia, blood pressure changes, dependency potential, withdrawal symptoms, pregnancy concerns, accidental pediatric exposure, vape-related lung injury [1][14][15].
• Bottom line: Legitimate therapeutic relevance in some settings, but carries clearest intoxication, psychiatric, and dose-related safety liabilities [1][13]-[15].

CBN:

• Evidence: Weak human evidence; marketing has moved ahead of data [12][16][17].
• Marketing vs. reality: Sleep and sedation claims widespread, but clinical support far thinner than market suggests [16][17].
• Sleep claim review: 2021 narrative review screened 99 human-study abstracts, reviewed eight full-text articles, found no clinical trials using validated sleep questionnaires or polysomnography that could substantiate strong sleep-promoting claims [16].
• Broader sleep literature: 2024 updated review concluded overall cannabinoid sleep research still doesn’t match real-world use scale; need for better-designed, adequately powered trials remains substantial [17].
• Chemical context: THC can degrade toward CBN under certain conditions, explaining why CBN is discussed in aging/oxidized cannabis chemistry contexts [12].
• Bottom line: Clearest example where cultural reputation is stronger than current clinical evidence base [16][17].

CBC:

• Evidence: Emerging, intriguing, overwhelmingly preclinical or review-based [18][19].
• Pharmacology: 2024 focused review argues CBC has distinct pharmacodynamics, pharmacokinetics, and receptor behavior relative to better-known cannabinoids, highlighting antinociceptive, antibacterial, and anti-seizure areas as especially interesting research targets [18].
• Older literature: Review of animal and in vitro work reports anti-inflammatory effects, reduced gut hypermobility, modest rodent analgesic activity, possible neurobiological or antiproliferative relevance — not yet strong evidence for patient-facing claims [19].
• Safety caveat: 2024 CBC review explicitly notes over-the-counter CBC products are sold despite little evidence establishing clinical efficacy or safety [18].
• Bottom line: Scientifically credible minor cannabinoid deserving more research, not already-validated clinical active [18][19].

Terpene profiles

Terpene claims need even stricter interpretation than cannabinoid claims. Much literature comes from isolated compounds, essential oils, non-cannabis plants, or preclinical models. Robust proof of clinically meaningful entourage effects in humans remains limited [20][29].

Limonene:

• Evidence: Largely review and preclinical, with useful safety literature [20]-[22].
• Potential activity: 2021 review describes multifunctional monoterpene with antioxidant, anti-inflammatory, cardioprotective, gastroprotective, immune-modulatory possibilities — overwhelming share from nonhuman/non-cannabis literature [21].
• Safety: Limonene oxidation products, especially hydroperoxides, are clinically relevant contact allergens important in patch-testing literature [22].
• Bottom line: Biologically active and widely discussed, but cannabis-specific therapeutic claims should stay conservative unless directly supported in humans [20]-[22].

Myrcene:

• Evidence: Mostly preclinical, very limited human evidence [20][23].
• Research: 2021 review describes anxiolytic, antioxidant, anti-inflammatory, analgesic properties, discusses possible mechanisms, but explicitly states human studies are lacking [23].
• Interpretation caution: Myrcene is often invoked as proven human sedative explaining couch-lock or sleep effects — stronger claim than human evidence currently supports [20][23].
• Bottom line: Plausible bioactive terpene, but compound-specific clinical claims about mood, pain, sedation remain far ahead of definitive human proof [23].

Caryophyllene:

• Evidence: Among most mechanistically interesting because of direct cannabinoid-system relevance, but still mostly preclinical [24].
• Why it stands out: 2021 focused review describes beta-caryophyllene as selective CB2 receptor agonist — unusual, making it especially relevant when discussing cannabis terpenes pharmacologically rather than purely aromatically [24].
• Research themes: Anti-inflammatory, immunomodulatory, antioxidant, neuroprotective, gastroprotective actions repeatedly discussed, but human clinical confirmation limited [24].
• Bottom line: Arguably strongest candidate for terpene with cannabinoid-system significance, but still should not be described as clinically proven for outcomes commonly attributed to it [24].

Pinene:

• Evidence: Promising preclinical literature, weak human clinical confirmation [20][25].
• Brain-health framing: 2021 review on pinene and linalool as terpene-based medicines for brain health found antioxidant, anti-inflammatory, neuroprotective signals justifying future study, but emphasized evidence is mostly preclinical and well-designed clinical trials are lacking [25].
• Interpretation caution: Claims that pinene reliably improves memory, sharpens attention, or counterbalances THC-related cognitive effects remain interesting hypotheses rather than settled clinical facts [20][25].
• Bottom line: Pinene deserves scientific attention, but strong cognition-related claims should be presented as exploratory [25].

Linalool:

• Evidence: Substantial preclinical interest, limited direct clinical confirmation [20][22][25][26].
• Research: Repeatedly discussed in relation to stress, mood, brain-health pharmacology. 2021 brain-health review found enough preclinical signal to justify continued investigation in neurological and psychiatric contexts, while emphasizing lack of robust human trials [25].
• Additional literature: Separate review discusses possible antidepressant mechanisms and neuropharmacologic relevance, but remains translational rather than definitive clinical story [26].
• Safety: As with limonene, oxidized linalool hydroperoxides are recognized allergens in dermatitis literature [22].
• Bottom line: Scientifically credible bioactive terpene, but current evidence supports cautious phrasing rather than firm therapeutic promises [22][25][26].

Humulene:

• Evidence: Translationally interesting, still early [20][27].
• Scoping review: 2024 review analyzed 340 articles, found broad preclinical evidence for anti-inflammatory and other biologic effects, with some rodent work suggesting cannabimimetic properties via CB1 and adenosine A2a pathways [27].
• Interpretation caution: Findings valuable for hypothesis generation, but do not yet establish consistent human efficacy across pain, inflammation, or mood outcomes [27].
• Bottom line: One of more interesting terpene research targets, but remains far from clinically settled [27].

Terpinolene:

• Evidence: Least clinically characterized terpene in this file [20][28].
• Systematic review: 2021 review screened 2,449 records, included 57 studies, concluded terpinolene has range of reported biological effects but evidence base is still dominated by in silico, in vitro, and animal studies rather than human trials [28].
• Interpretation caution: Even recent cannabis entourage reviews frame terpene benefits as exploratory, not as established compound-specific clinical effects [20].
• Bottom line: Biologically interesting, but among listed terpenes remains especially underdeveloped clinically [20][28].

Research limits and interpretation

• Evidence base is highly uneven. CBD and delta-9 THC can support most detailed human-facing statements; rest require more caution [1]-[29].
• Whole-cannabis extract data, purified-molecule data, semisynthetic cannabinoid data, and terpene-only data are not interchangeable. Common error is letting evidence from one category stand in for another.
• Minor cannabinoids and terpenes are commercially interesting precisely because they are underexplored, but that also means claims around them often become inflated.
• Product quality matters as much as molecule identity. Labeling inaccuracies, contamination, synthesis byproducts, dose variability, and route-dependent pharmacokinetics all materially affect interpretation in real-world products [1][10][11][14].
• For THCa particularly, chemistry is destiny: storage and heating can change actual exposure profile by converting acidic cannabinoids into neutral cannabinoids such as THC [12].

Common overstatements to avoid

• Overstatement: CBN is clinically proven sleep cannabinoid.
  More accurate: Specific sleep evidence for CBN remains weak and dated, with no strong validated-trial base yet identified [16][17].
• Overstatement: Myrcene is proven human sedative that reliably explains couch-lock.
  More accurate: Myrcene has plausible preclinical bioactivity, but direct human proof for that common claim is limited [20][23].
• Overstatement: Terpenes in general have proven entourage effects in patients.
  More accurate: Entourage hypotheses are influential and worth studying, but robust clinical proof remains limited and highly compound-specific [20][29].
• Overstatement: THCa is always nonpsychoactive.
  More accurate: THCa itself is not THC, but heating and processing can convert THCa into THC, changing effective exposure [12].
• Overstatement: Delta-8 THC is safe because it is hemp-derived.
  More accurate: Delta-8 THC is psychoactive, pharmacologically close to delta-9 THC, and often entangled with manufacturing and testing concerns [9]-[11].

Practical takeaways for the formulas in this document

• Most evidence-developed actives in these formulas are CBD and delta-9 THC.
• Delta-8 THC is not trivial or purely mild ingredient; it is psychoactive cannabinoid with less robust safety and efficacy characterization than delta-9 THC.
• THCa meaningfully changes with processing and should not be interpreted same way in raw, gently handled, and heated formats.
• CBG, CBN, and CBC are scientifically credible but clinically immature compared with CBD and THC.
• Listed terpenes are likely highly relevant to aroma, flavor, and potentially some biologic activity, but compound-specific human therapeutic claims should be made carefully and only where directly supported.

RSO Sublingual Oil Formula

Cannabinoid	Amount
CBD	4,500 mg
CBG	3,000 mg
Delta-8 THC	6,000 mg
THCa	1,500 mg
Delta-9 THC	90 mg
CBN	750 mg
CBC	750 mg
Total Cannabinoids	16,590 mg

• Live Terpenes: 5% (limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene)
• Format: 30 mL bottle with graduated dropper (0.1 mL increments)
• Active per mL: 553 mg cannabinoids
• Carrier: Organic MCT oil
• Onset: 15-45 minutes (sublingual)
• Duration: 4-6 hours
• Doses per bottle: 40-60 depending on serving size

For Dededo customers: This concentration means you’re getting maximum therapeutic value per milliliter, which matters when shipping to a remote location. The graduated dropper allows precise titration whether you’re microdosing for daytime functionality or using full doses for nighttime relief.

RSO Vape Cartridge Formula

Cannabinoid	Percentage
CBD	30%
CBG	20%
Delta-8 THC	15%
THCa	10%
CBN	10%
CBC	10%

• Live Terpenes: 5%+
• Format: 1-gram 510-thread cartridge
• Total cannabinoids: 900+ mg
• Compatibility: Works with any standard 510-thread battery available at vape shops in Dededo or through online retailers
• Onset: 1-2 minutes
• Duration: 2-4 hours

For Dededo customers: The vape format is ideal for breakthrough pain, panic attacks, or acute nausea that may strike during a family gathering, at work, or while traveling around the island. The instant onset provides relief when you can’t wait 45 minutes.

Terpene Profile (Both Products)

• Limonene: Citrus-bright aroma (think local calamansi lemons)
• Myrcene: Earthy, musky base note
• Caryophyllene: Pepper/spice (like local donne’ sali chili pepper)
• Pinene: Forest-fresh (evokes Guam’s pine trees and lush jungle)
• Linalool: Floral, lavender-like calming scent
• Humulene: Earthy, woody depth
• Terpinolene: Piney, fruity, sparkling top notes

For Dededo residents familiar with Guam’s rich plant life — from the citrus groves to the jungle canopy — these terpenes create a sensory experience that connects to the island’s natural environment while delivering therapeutic potential.

Final Thoughts for Dededo

If you’re in Dededo reading this, you’re likely at a crossroads. Maybe you’re tired of pharmaceutical side effects. Maybe you’re supporting a loved one through cancer treatment at Guam Memorial. Maybe you’re a veteran carrying wounds that the VA clinic can’t fully heal. Maybe you’re just curious and want honest information before trying something new.

We wrote this guide because we believe you deserve the same transparency we give our Houston neighbors. We can’t be there in person to shake your hand at the Dededo Farmers Market or sit with you at Jeff’s Pirates Cove, but we can be here in spirit — through this comprehensive education, through our published formulas, through our commitment to shipping legally and reliably to Guam.

The products we make in Houston are crafted with the same care and precision that Colin learned while keeping Bentley alive for ten years. The formulas that emerged from that decade of love and desperation are now available to you in Dededo. Whether you purchase from us or use our open-source recipes to make your own, our mission is accomplished if you have the best possible version to base your opinion on — to give it a fair shot as to whether it’s right or wrong for you.

OilWell Cannabis is more than a brand. It is a promise that we will always strive to deliver the best, most thoughtful cannabis products available. We are not here to follow trends. We are here to set them. And as we continue to grow, our focus remains on maintaining the same level of integrity, creativity, and commitment that defined us from the day Bentley got up, walked across the room, and brought his ball to play.

Order for Dededo delivery: Visit oilwellcbd.com or call (832) 416-2816. We ship to Guam with full documentation, and our customer service team will walk you through any questions about customs, dosing, or legal compliance specific to your situation in Dededo.

Agricultural Improvement Act of 2018 (Farm Bill) compliant. Hemp-derived. Contains less than 0.3% delta-9 THC. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Must be 21+ to purchase. Buyer assumes responsibility for compliance with Guam law.